The pharmaceutical industry relies heavily on a consistent supply of high-quality chemical intermediates to produce effective medicines. Among these essential compounds is Ethyl 3,4-Dihydroxybenzoate (CAS: 3943-89-3), a key intermediate particularly recognized for its role in the synthesis of Erlotinib. For professionals in drug development and manufacturing, understanding its significance and sourcing strategies is crucial.

Ethyl 3,4-Dihydroxybenzoate, also referred to by its common synonym Ethyl Protocatechuate, is characterized by its molecular formula C9H10O4 and a molecular weight of 182.17300. It typically presents as a white crystalline powder, with purity levels often exceeding 99%. Its physical properties, such as a melting point in the range of 132-134 °C, are critical specifications for quality assurance. When you are looking to 'buy' this intermediate, ensuring it meets these standards from a reputable 'pharmaceutical intermediate supplier' is paramount.

The primary application driving the demand for Ethyl 3,4-Dihydroxybenzoate is its critical function as an intermediate in the synthesis of Erlotinib and Erlotinib Hydrochloride. These drugs are vital for treating certain types of cancer, making the quality and availability of this precursor a significant factor in pharmaceutical production. Pharmaceutical companies seek reliable 'manufacturers' who can provide consistent quality and scale, enabling efficient API production.

Sourcing strategies for such intermediates often involve identifying experienced 'chemical manufacturers in China' known for their expertise in complex organic synthesis. These suppliers can offer competitive pricing for bulk orders of Ethyl 3,4-Dihydroxybenzoate, coupled with the necessary quality documentation, such as Certificates of Analysis (CoA). Procurement managers must carefully evaluate potential suppliers based on their production capacity, quality control measures, and ability to meet stringent regulatory requirements.

The 'price of Ethyl 3,4-Dihydroxybenzoate' can fluctuate based on market demand and supply dynamics, but the underlying requirement for high purity and reliable delivery remains constant. Engaging with a 'CAS 3943-89-3 supplier' that offers transparency in its processes and supports your specific project needs, whether for R&D or large-scale manufacturing, is key to building a robust supply chain.

In conclusion, Ethyl 3,4-Dihydroxybenzoate is a vital pharmaceutical intermediate whose quality directly impacts the production of essential cancer therapies. By prioritizing a partnership with an experienced and quality-focused manufacturer or supplier, companies can ensure they obtain this critical compound reliably and efficiently, supporting the advancement of healthcare solutions.